Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1–98
Abstract Background The androgen receptor (AR) is an emerging prognostic marker and therapeutic target in breast cancer. AR is expressed in 60–80% of breast cancers, with higher prevalence among estrogen receptor-positive (ER+) tumors. Androgen treatment inhibits ER signaling in ER+/AR+ breast cance...
Main Authors: | Kevin H. Kensler, Meredith M. Regan, Yujing J. Heng, Gabrielle M. Baker, Michael E. Pyle, Stuart J. Schnitt, Aditi Hazra, Roswitha Kammler, Beat Thürlimann, Marco Colleoni, Giuseppe Viale, Myles Brown, Rulla M. Tamimi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-02-01
|
Series: | Breast Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13058-019-1118-z |
Similar Items
-
Influence of the anti‐oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review
by: Djordje Marina, et al.
Published: (2023-01-01) -
Tratamiento sistémico actual para cáncer de mama avanzado hormono-dependiente
by: Benjamín Walbaum, et al.
Published: (2023-05-01) -
The effect of palm pollen and letrozole + tamoxifen regimen in the treatment of infertile women: A double-blind randomized clinical trial
by: Athar Rasekhjahromi, et al.
Published: (2022-06-01) -
Case studies on clinical experience of targeted therapy ribociclib in combination with letrozole in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
by: M A Frolova, et al.
Published: (2018-06-01) -
Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer
by: Simon P. Langdon, et al.
Published: (2020-06-01)